DR Reddys Laboratories Ltd (RDY)

Listed in the US · Manufacturing · Pharmaceutical preparations

$14.11

As of 29 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close $14.11 on 29 Oct 2026. The share price traded between $11.36 and $15.67 (intraday) over the last 12 months.

The closes as a table

Date	Close

Key figures

1-year range (intraday)

Low $11.36High $15.67

Market cap$11.8Blast close × shares

P/E26.2on year to Mar 2026 profit

Return on equity11.4%year to Mar 2026

EBITDA margin21.2%year to Mar 2026

Debt to equity0.05year to Mar 2026

Net margin12.8%year to Mar 2026

Dividend yield0.59%last 12 months

The share price and market cap are in US dollars. Reported results are in INR million, as the company files them; P/E and the dividend yield set them against the dollar price at the exchange rate when the page was built, while the table and the margins stay in INR.

Price trend

Stage 1 (basing): the 150-day average has stopped falling, or the price has climbed above a falling average, for 10 trading days.
Supertrend (10, 3): the price has closed above the line for 29 trading days.

Revenue and profit

RevenueNet profitINR million

0100,000200,000300,000400,000

Mar 2022Revenue 214,391Net profit 23,568Mar ’22

Mar 2023Revenue 245,879Net profit 45,067Mar ’23

Mar 2024Revenue 279,164Net profit 55,684Mar ’24

Mar 2025Revenue 325,535Net profit 56,544Mar ’25

Mar 2026Revenue 335,933Net profit 42,850Mar ’26

Year	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	214,391	245,879	279,164	325,535	335,933
Net profit	23,568	45,067	55,684	56,544	42,850
EBITDA margin	19.3%	28.4%	29.6%	27.3%	21.2%
Borrowings	6,763	6,082	7,297	8,721	18,206

INR million. Over three years, compounded: revenue grew 11.0% a year, net profit fell 1.7% a year.

Recent filings

Questions about DR Reddys Laboratories Ltd

What is DR Reddys Laboratories Ltd's market value?

DR Reddys Laboratories Ltd's market value is $11.8B as of 29 Oct 2026 close: the last close times the shares in issue. Its P/E is 26.2, the last close over earnings per share for the last four reported quarters.

Go further with RDY

Free to start: test a trading idea on RDY's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Test a strategy on RDY Open the full deep dive

Same industry

The largest companies in the same industry (Pharmaceutical preparations), by market value.

Novartis AG (NVS)Astrazeneca PLC (AZN)Novo Nordisk A S (NVO)Sanofi (SNY)GSK plc (GSK)Takeda Pharmaceutical Co Ltd (TAK)Teva Pharmaceutical Industries Ltd (TEVA)BeOne Medicines Ltd. (ONC)Genmab A/s (GMAB)Ascendis Pharma A/S (ASND)Abivax S.A. (ABVX)Belite Bio, Inc (BLTE)

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

Last close: the closing price on the date shown. The page follows the market's close; it doesn't show prices during the session. A price older than the market's latest close, or a last trade that isn't a close, is labelled as the last price, with the session it is from.
1-year range: the lowest and highest prices traded during the sessions of the last year (intraday), so they can lie outside the closing prices.
Market cap: the last close times the shares in issue. It is n/a when it doesn't agree with the company's own reported figures (for example a depositary share counted as an ordinary share).
P/E: the last close divided by earnings per share over the last four reported quarters, the profit that belongs to the company's shareholders per share, as the company reports it. So P/E can differ from market cap divided by the net profit shown (a different share count, or the profit before minority interests; where they differ by more than 10%, a note under the figures gives both). A company that reports only once a year has its latest year's earnings, and the P/E names that year; when that year ended more than about 15 months before the close, P/E is n/a. A loss has no P/E. Above 1,000 it is n/a.
EBITDA margin: operating profit before depreciation, interest and tax (and before other income), as a share of revenue in the latest reported year, the table's last column.
Net margin: net profit as a share of revenue in the latest reported period. Return on equity, the margins and debt to equity each use inputs from that one year; if one input is missing for it, the figure is n/a. When that year ended more than about 15 months before the close, they are n/a too.
Dividend yield: every dividend per share with an ex-date in the 12 months to the last close, special dividends included, as a share of that close. n/a when the company's dividends couldn't be read.
n/m: not meaningful. A margin or return beyond ±1,000% comes from revenue or equity near zero, so it is not shown as a number.